The pharmaceutical-grade active pharmaceutical ingredient 2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one is supplied as a crystalline powder for oral and injectable dosage forms, including tablet, capsule, granule, and injection presentations. The CAS Registry Number is 571190-30-2; the molecular formula is C13H14ClN3O and the calculated molecular weight is 263.72 g/mol. Supplier-specific model designations usually distinguish oral-grade and injectable-grade material; for example, API-2C8CP-5M-PP7-ORL identifies an oral grade and API-2C8CP-5M-PP7-INJ identifies an injectable grade, but these model codes are not harmonized across manufacturers. The 2-chloro substituent on the pyrimidine ring, the 8-cyclopentyl group at the fused-ring nitrogen, and the 5-methyl substituent adjacent to the 7(8H)-one carbonyl define the stability and processing profile of this API relative to other pyrido[2,3-d]pyrimidin-7(8H)-one derivatives.

The 2-chloro group is electrophilic; formulations should avoid prolonged contact with primary amine buffers above pH 8.0 because nucleophilic displacement can generate substituted pyrimidine impurities. Published quantitative solubility, permeability, and forced-degradation data for this exact substance remain limited. Therefore, each manufacturer’s dossier, certificate of analysis, and registered specification remain the controlling reference for product-specific release limits.

Quality Attributes and Release Specifications for Oral and Injectable Processing

Specification frameworks follow ICH Q6A decision trees for new drug substances, with route-specific limits applied to parenteral dosage forms. Identity is confirmed by infrared absorption spectrophotometry against a qualified reference standard or by HPLC retention time using USP <621>. Assay on the anhydrous, solvent-free basis is typically controlled at 98.0% to 102.0%. Organic impurities are reported and identified according to ICH Q3A thresholds: reporting threshold 0.05%, identification threshold 0.10%, and qualification threshold 0.15% for a maximum daily dose not exceeding 2 g/day. Total impurities above 0.10% are limited by the registered specification. Residual solvents are controlled according to ICH Q3C; if synthesis uses acetic acid, ethyl acetate, or ethanol, class 3 limits apply at 5000 ppm or 0.5% unless otherwise justified. Water content by Karl Fischer titration, USP <921>, is route-dependent. Injectable-grade material typically carries a water limit of 0.2%, while oral-grade material may allow up to 0.5%. Residue on ignition by USP <281> is typically controlled at 0.1% or lower for injectable use. Elemental impurities are controlled under ICH Q3D and measured by ICP-MS; oral and parenteral permitted daily exposures differ by route.

How Does the 8-Cyclopentyl Substituent Affect Solid-State and Formulation Behavior?

The 8-cyclopentyl group increases nonpolar surface area relative to 8-methyl or unsubstituted 8H analogues, which lowers aqueous solubility and shifts retention time in reversed-phase HPLC toward higher organic mobile-phase composition. The cyclopentyl ring is flexible but less planar than an aromatic ring; this can influence crystal packing and may reduce crystallinity or generate multiple polymorphs under different crystallization solvents. Published single-crystal and differential scanning calorimetry data for this exact API are limited; therefore, solid-state characterization by XRPD under USP <941> and DSC under USP <891> is required during process validation. Formulators should establish the anhydrous or hydrate designation by moisture-sorption analysis under USP <1245> or equivalent DVS experiments.

Compared with more hydrophilic 7(8H)-one analogues, the compound may require particle-size reduction, surfactant addition, or solvent-mediated granulation for oral absorption. For direct compression, agglomerates are delumped by a cone mill or a high-shear mixer, and blend uniformity is assessed according to USP <905>. If the API is micronized, electrostatic adhesion can reduce flow; mixing with silicon dioxide at 0.5% to 1.0% may be used to improve flowability, but the addition level must be optimized to avoid over-blending and segregation.

For tablet manufacture, the API is typically dispersed in a binder solution during wet granulation or co-milled with dry binders prior to roller compaction. The 2-chloro substituent requires a non-aqueous granulation solvent if the material demonstrates hydrolytic sensitivity above 40°C; however, published forced-degradation data for this specific configuration are limited, so compatibility with water must be confirmed by stress testing under ICH Q1A. Granule moisture after fluid-bed drying is controlled by loss on drying, USP <731>, and the granulation end point is monitored by power consumption or impeller torque in a high-shear mixer. Capsule formulations may use dry blending and tamp filling if the powder exhibits acceptable bulk density; otherwise, low-dose capsules require geometric dilution or slugging to maintain content uniformity.

When Injectable Processing Imposes Aseptic and Particulate Requirements

Injectable applications of 2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one require a low-endotoxin, controlled-particulate grade. The API must be dissolved or suspended in a vehicle that is compatible with the 2-chloro electrophile; primary amine buffers above pH 8.0 are unsuitable because they may promote nucleophilic displacement. Terminal sterilization by moist heat at 121°C for 15 min should be introduced only after thermal-stability data demonstrate a sterility assurance level of 10^-6 without exceeding the impurity specification. Where heat lability is documented, aseptic filtration through a 0.22 µm sterilizing-grade filter is applied, and the filling line is qualified for media fills under EU GMP Annex 1. Lyophilized injection formulations typically use mannitol or trehalose as bulking agents; dielectrics and fill volume are governed by container-closure integrity testing under USP <1207>. Subvisible particulate counts in injectable fluids are tested by light obscuration per USP <788> or Ph. Eur. 2.9.19, with limits for particles ≥ 10 µm and ≥ 25 µm as specified by the compendium.

In tablet and capsule manufacture, the API can be processed by wet granulation, dry granulation, or direct compression after the particle-size distribution is matched to the filler system. For wet granulation, the API is suspended or dissolved in a binder solution; if the batch record does not permit water at elevated temperature, a hydroalcoholic or acetone-based granulating solvent is selected only after closed-vessel compatibility and residual solvent removal are confirmed. High-shear granulators with 10 L to 100 L bowl capacity are operated with impeller tip speeds of 2 m/s to 6 m/s and chopper speeds of 1500 rpm to 3000 rpm; these parameters are developed experimentally to produce granule mean diameter between 150 µm and 500 µm. The wet mass is dried in a fluid-bed dryer with inlet air temperature between 40°C and 60°C, and the final loss on drying is controlled by USP <731>. Dry granulation by roller compaction is preferred when the 2-chloro substituent shows hydrolytic sensitivity; ribbon density between 0.9 g/cm³ and 1.2 g/cm³ is milled through an oscillating granulator fitted with a 1.0 mm screen. Direct compression blends are mixed in a bin blender at 12 rpm to 25 rpm for 150 to 300 revolutions, followed by magnesium stearate lubrication for 3 min to 5 min to avoid excessive hydrophobic film formation.

Compressed tablets are tested for hardness, friability, disintegration, and dissolution using USP <1217> for dissolution apparatus, USP <701> for disintegration, and USP <1216> for friability. Immediate-release tablet cores typically exhibit tensile strength between 1.5 MPa and 2.5 MPa, friability not more than 1.0%, and disintegration not more than 15 min in water at 37°C. Dissolution acceptance criteria are product-specific; a single-point test at Q=75% in 45 min is not assumed and must be established from the dissolution profile. For capsules, powder flow and bulk density are measured by USP <616>; a compressibility index below 20% indicates acceptable flow for automatic capsule filling, while higher values require glidant adjustment or granulation.

What Distinguishes This 2-Chloro-8-Cyclopentyl Scaffold From Other Pyrido[2,3-d]pyrimidin-7(8H)-one APIs?

Compared with 8-methyl, 8-ethyl, or 8-aryl pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, the 8-cyclopentyl modification confers increased lipophilicity and may reduce aqueous solubility. The 5-methyl group introduces steric hindrance around the carbonyl, potentially influencing metabolic clearance and hydrogen-bonding with crystal formers. The 2-chloro group remains available for salt or cocrystal screening, but its electrophilic nature differentiates this API from 2-amino or 2-unsubstituted analogues that are less reactive toward nucleophilic excipients. These differences require route-specific formulation: oral formulations may tolerate higher residual water and larger particle size, while injectable formulations demand low endotoxin and controlled particle burden. The choice of a tablet, capsule, granule, or injection presentation therefore depends on solubility, permeability, and stability data rather than on a single universal specification.

For granule-based sachet or suspension presentations, the API is blended with sugar spheres or mannitol, and a binder solution is sprayed in a fluid-bed granulator. Exhaust air temperature and dew point are controlled to avoid hydrate formation; if the API is non-hygroscopic but shows poor flow, dry granulation by roller compaction may be used with ribbon density 0.9 g/cm³ to 1.2 g/cm³ and milling to a target granule size of 150 µm to 500 µm. These process targets are not product-specific release limits and must be verified in the pharmaceutical development report. Published data for this specific configuration are limited; thus, formulation feasibility batches are required before scale-up to commercial batch sizes.